Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Urea Cycle Drug Coverage Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedPremera Blue Cross of WashingtonPolicy 5.01.611

    Pharmacologic Treatment of Urea Cycle Disorders

    Customize your policy alerts

    Sign up for premerabluecrossofwashington Policy 5.01.611 alerts

    Get alerted when Policy 5.01.611 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage and authorization requirements for drugs used to treat urea cycle disorders, hyperammonemia, hyperargininemia, and specified organic acidemias. It applies to providers requesting coverage under the pharmacy or medical benefit.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyPharmacologic Treatment of Urea Cycle Disorders
    Policy CodePolicy 5.01.611
    Change TypeModified
    Effective DateFebruary 5, 2027
    Last ReviewOct 13, 2026
    Next Review DateNot specified
    Key ActionDocument the applicable diagnosis, genetic or laboratory confirmation, prior therapy, dietary protein restriction, specialist involvement, functional testing, and dosing requirements for the requested drug.
    SourceLink
    POLICY UPDATE CHANGES

    The Ravicti criterion was updated from requiring failure of Buphenyl to requiring failure of generic sodium phenylbutyrate.

    Carbaglu was given an added indication for acute hyperammonemia due to propionic acidemia or methylmalonic acidemia when used with standard-of-care treatment.

    Pheburane was added for treatment of urea cycle disorders in adult and pediatric individuals.

    Added coverage for Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia.

    Added generic glycerol phenylbutyrate with the same criteria as Ravicti (glycerol phenylbutyrate).

    Clarified that non-formulary exception review authorizations for drugs listed in the policy may be approved for up to 12 months.

    Clarified that medications listed in the policy are subject to the product's FDA dosage and administration prescribing information.

    9Drug products or generic equivalents addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Up to 3 yearsMaximum approval period for specified continuing therapies
    Up to 12 monthsMaximum approval period for Loargys reviews
    0.2 mg/kg once weeklyLoargys dose limitation
    J1818HCPCS code for Loargys injection

    Covered Drugs and Investigational Uses

    Buphenyl, Olpruva, and Pheburane

    Covered when all of the following are met:

    Brand sodium phenylbutyrate products: Buphenyl, Olpruva, or Pheburane is used as adjunctive therapy for the chronic management of a urea cycle disorder; genetic testing documents deficiency of carbamoyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS); the individual has tried generic sodium phenylbutyrate first and had an inadequate response or intolerance; and a dietary protein restriction plan is documented.

    Documentation of the inadequate response or intolerance to generic sodium phenylbutyrate is required.

    Generic sodium phenylbutyrate

    Covered when all of the following are met:

    Generic sodium phenylbutyrate is used as adjunctive therapy for the chronic management of a urea cycle disorder; genetic testing documents deficiency of carbamoyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS); and a dietary protein restriction plan is documented.

    Carbaglu

    Covered when the applicable indication and all associated requirements are met:

    ONE of the following Carbaglu indications

    • NAGS deficiency: Carbaglu is used for acute or chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; genetic testing documents deficiency of the hepatic enzyme NAGS; and the individual has tried generic carglumic acid first and had an inadequate response or intolerance.

      Documentation of the inadequate response or intolerance to generic carglumic acid is required.

    • Propionic acidemia or methylmalonic acidemia: Carbaglu is used as adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA); and the individual has tried generic carglumic acid first and had an inadequate response or intolerance.

      Documentation of the inadequate response or intolerance to generic carglumic acid is required.

    Generic carglumic acid

    Covered for either of the following indications:

    ONE of the following indications

    • NAGS deficiency: Generic carglumic acid is used for acute or chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, with genetic testing documenting deficiency of the hepatic enzyme NAGS.
    • Propionic acidemia or methylmalonic acidemia: Generic carglumic acid is used as adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA).

    Loargys

    Covered when all of the following are met:

    Loargys criteria: The individual is at least 2 years old; has a documented diagnosis of arginase 1 deficiency (ARG1-D) confirmed by persistently elevated plasma arginine levels, pathogenic variants in arginase 1 (ARG1), or decreased erythrocyte ARG1 activity; has a documented dietary protein restriction plan; baseline GMFM-E and 2-minute walk test (2MWT) documentation is provided when the individual is at least 5 years old; the medication is prescribed by or in consultation with a medical geneticist or neurologist; and the dose is limited to 0.2 mg/kg once weekly.Age >= 2 years; dose <= 0.2 mg/kg once weekly

    Baseline GMFM-E and 2MWT results are not required for individuals younger than 5 years.

    Ravicti and generic glycerol phenylbutyrate

    Covered when all of the following are met:

    Glycerol phenylbutyrate products: Ravicti or generic glycerol phenylbutyrate is used as adjunctive therapy for the chronic management of a urea cycle disorder; the individual has tried and failed generic sodium phenylbutyrate unless there is a contraindication to its use; and a dietary protein restriction plan is documented.

    Documentation of failure of generic sodium phenylbutyrate or the contraindication is required.

    Investigational uses

    All other uses are investigational:

    Investigational uses: Uses of the medications listed in this policy that do not meet the stated medical-necessity criteria are considered investigational.

    The medications are subject to the applicable product's U.S. Food and Drug Administration dosage and administration prescribing information.

    Uses of the medications listed in this policy that do not meet the stated medical-necessity criteria are considered investigational. The medications remain subject to the applicable product’s FDA dosage and administration prescribing information.

    In the summarized pegzilarginase studies, common exclusion criteria included symptomatic hyperammonemia and active infections.

    The PEACE study excluded individuals with extreme mobility impairment, a prior liver or hematopoietic transplant, or use of botulinum toxin-containing regimens.

    This medical policy does not apply to Medicare Advantage.

    Coding and Clinical Thresholds

    HCPCSHCPCSCovered
    J1818Injection, pegzilarginase-nbln (Loargys), 0.05 mg
    Loargys minimum age
    MedicationLoargys (pegzilarginase-nbln)
    Minimum age2 years or older
    Coverage applicationTreatment of hyperargininemia due to arginase 1 deficiency
    Loargys dose limitation
    MedicationLoargys (pegzilarginase-nbln)
    Dose limitationNo greater than 0.2 mg/kg
    Administration frequencyOnce weekly

    Authorization, Documentation, and Denial Risks

    Documentation Required

    Brand Sodium Phenylbutyrate Criteria

    Buphenyl, Olpruva, and Pheburane may be considered medically necessary for chronic adjunctive treatment of a urea cycle disorder when the required diagnosis, prior therapy, and dietary documentation are submitted.

    • Adjunctive therapy for chronic management of a urea cycle disorder.
    • Genetic testing documents deficiency of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
    • The individual has tried generic sodium phenylbutyrate and had an inadequate response or intolerance; documentation is required.
    • A documented dietary protein restriction plan is in place.
    Documentation Required

    Generic Sodium Phenylbutyrate Criteria

    Generic sodium phenylbutyrate may be considered medically necessary for chronic adjunctive treatment of urea cycle disorders when genetic and dietary documentation is provided.

    • Used as adjunctive therapy for chronic management of a urea cycle disorder.

    Clinical Background

    Urea cycle disorders are inherited deficiencies of enzymes or transporters involved in converting ammonia to urea. Impaired ammonia metabolism can produce hyperammonemia, which may lead to neurologic injury, cerebral edema, coma, and death. Management is directed at controlling ammonia and preventing hyperammonemic crises through dietary protein restriction, amino acid supplementation when appropriate, and nitrogen-scavenging or related pharmacologic therapy.

    Definitions and Abbreviations

    Gross Motor Function Measure part E
    AssessmentGross Motor Function Measure part E (GMFM-E)
    Function evaluatedWalking, running, and jumping
    Scoring contextScore ranges from 0 to 72; lower scores indicate greater impairment
    Hyperammonemia
    TermHyperammonemia
    DefinitionAn elevated plasma ammonia concentration
    Laboratory contextGenerally greater than 100 to 150 micromol/L in a urea cycle disorder

    Initial Authorization

    Initial authorization

    Initial authorization requires all applicable drug-specific criteria to be met:

    Initial therapy: The requested drug is used for a covered indication and satisfies the applicable diagnosis, genetic or laboratory confirmation, prior therapy, dietary protein restriction, specialist, functional testing, and dosing requirements stated in this policy.

    The specific requirements depend on the requested medication and indication.

    Continuation and Reauthorization

    General continuation therapy

    Continuation authorization may be granted when all applicable requirements are met:

    General continuation: For Buphenyl, Carbaglu, generic carglumic acid, Olpruva, Pheburane, Ravicti, generic glycerol phenylbutyrate, and generic sodium phenylbutyrate, chart notes demonstrate that the individual continues to show a positive clinical response to therapy and the drug-specific coverage criteria remain met.

    These drugs may be approved for up to 3 years.

    Loargys reauthorization

    Loargys reauthorization requires all of the following:

    Loargys continuation: The individual has a plasma arginine level less than 200 micromoles per liter; and, for individuals at least 5 years of age, documentation shows improvement from baseline in both the GMFM-E score and the 2-minute walk test (2MWT).Plasma arginine < 200 micromoles per liter; improvement in GMFM-E and 2MWT from baseline when age >= 5 years

    Preferred Product Requirements

    StepTry firstRequested therapyRequirement
    1Generic sodium phenylbutyrateBuphenyl, Olpruva, or PheburaneThe individual must have an inadequate response or intolerance to generic sodium phenylbutyrate; documentation is required.
    StepTry firstRequested therapyRequirement
    1Generic carglumic acidCarbagluThe individual must have an inadequate response or intolerance to generic carglumic acid; documentation is required.
    StepTry firstRequested therapyRequirement
    1Generic sodium phenylbutyrateRavicti or generic glycerol phenylbutyrateThe individual must try and fail generic sodium phenylbutyrate unless there is a contraindication.
    StepRequired prior therapyRequested therapyRequirement
    1Generic sodium phenylbutyrateRavictiThe individual must have tried and failed generic sodium phenylbutyrate.

    Dose and Quantity Limits

    Loargys quantity limit
    MedicationLoargys (pegzilarginase-nbln)
    Quantity limit0.2 mg/kg
    FrequencyOnce weekly

    Administration Setting

    Note

    Initiate Loargys in an equipped healthcare setting

    Initiate pegzilarginase treatment in a healthcare setting with cardiopulmonary resuscitation equipment present because of the boxed warning for hypersensitivity and anaphylaxis.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyPharmacologic Treatment of Urea Cycle Disorders
    Policy CodePolicy 5.01.611
    Change TypeModified
    Effective DateFebruary 5, 2027
    Last ReviewOct 13, 2026
    Next Review DateNot specified
    Key ActionDocument the applicable diagnosis, genetic or laboratory confirmation, prior therapy, dietary protein restriction, specialist involvement, functional testing, and dosing requirements for the requested drug.
    SourceLink
    On This Page
    Covered Drugs and Investigational UsesCoding and Clinical ThresholdsAuthorization, Documentation, and Denial RisksClinical BackgroundDefinitions and AbbreviationsInitial AuthorizationContinuation and ReauthorizationPreferred Product RequirementsDose and Quantity LimitsAdministration Setting
    Loargys continuation plasma arginine
    MedicationLoargys (pegzilarginase-nbln)
    Continuation thresholdPlasma arginine less than 200 micromoles per liter
    Review contextRequired for reauthorization
    GMFM-E and 2MWT age applicability
    AssessmentsGross Motor Function Measure part E (GMFM-E) and 2-minute walk test (2MWT)
    Age 5 years or olderRequired at baseline and for continuation; continuation requires improvement from baseline in both assessments
    Under 5 yearsGMFM-E and 2MWT are not required at baseline
    Hyperammonemic episode eligibility
    ConditionAcute hyperammonemia due to propionic acidemia or methylmalonic acidemia
    Eligible episodeAdmission to the hospital with a plasma ammonia level of at least 70 micromol/L
    Treatment contextCarbaglu or placebo was administered with standard of care for 7 days or until hospital discharge, whichever occurred earlier
    Carbaglu primary endpoint
    MedicationCarbaglu (carglumic acid)
    Primary endpointTime from the first dose to the earlier of plasma ammonia level of 50 micromol/L or less or hospital discharge
    Normal-range thresholdPlasma ammonia level of 50 micromol/L or less
    PEACE baseline plasma arginine
    StudyPEACE
    Baseline eligibilityPlasma arginine of at least 250 μmol/L
    PopulationPatients aged 2 years or older with documented arginase 1 deficiency
    Study 101A baseline plasma arginine
    StudyStudy 101A
    Baseline eligibilityPlasma arginine greater than 200 μmol/L
    PopulationPatients aged 2 years or older with documented arginase 1 deficiency
    Pegzilarginase plasma arginine response
    Response thresholdPlasma arginine less than 200 μmol/L
    Normal range40–115 μmol/L
    Clinical response contextWith pegzilarginase, mean plasma arginine decreased below 200 μmol/L and reached the normal range by 12 weeks
    Normal plasma ammonia reference
    ReferenceUpper limit of normal for plasma ammonia
    Value35 μmol/L
    Clinical contextThe Carbaglu endpoint used a separate plasma ammonia threshold of 50 micromol/L or less
  1. Genetic testing documents deficiency of CPS, OTC, or AS.
  2. A documented dietary protein restriction plan is in place.
  3. Documentation Required

    Carbaglu Documentation Requirements

    Carbaglu may be considered medically necessary for acute or chronic hyperammonemia due to NAGS deficiency, or as adjunctive therapy to standard of care for acute hyperammonemia due to PA or MMA. Submit the applicable diagnosis and prior generic carglumic acid documentation.

    • For NAGS deficiency: genetic testing documents deficiency of the hepatic enzyme NAGS.
    • For acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA): documentation supports the indication and adjunctive use with standard of care.
    • The individual has tried generic carglumic acid and had an inadequate response or intolerance; documentation is required.
    Documentation Required

    Generic Carglumic Acid Criteria

    Generic carglumic acid may be considered medically necessary for acute or chronic hyperammonemia due to NAGS deficiency, or as adjunctive therapy to standard of care for acute hyperammonemia due to PA or MMA.

    • For NAGS deficiency, genetic testing documents deficiency of the hepatic enzyme NAGS.
    • For PA or MMA, documentation supports acute hyperammonemia and adjunctive use with standard of care.
    Documentation Required

    Loargys Eligibility and Documentation

    Loargys may be considered medically necessary for hyperargininemia when the individual meets the age, diagnosis, laboratory, dietary, specialist, dose, and baseline functional-assessment requirements.

    • Individual is at least 2 years old.
    • ARG1 deficiency is documented by at least one of the following: persistently elevated plasma arginine, pathogenic ARG1 variants, or decreased erythrocyte ARG1 activity.
    • A documented dietary protein restriction plan is in place.
    • Baseline GMFM-E and 2-minute walk test (2MWT) results are submitted; neither test is required for individuals younger than 5 years.
    • Prescribed by or in consultation with a medical geneticist or neurologist.
    • Dose does not exceed 0.2 mg/kg once weekly.
    Prior Authorization

    Glycerol Phenylbutyrate Criteria

    Ravicti and generic glycerol phenylbutyrate may be considered medically necessary for chronic adjunctive management of a urea cycle disorder after generic sodium phenylbutyrate therapy, unless generic sodium phenylbutyrate is contraindicated.

    • Used as adjunctive therapy for chronic management of a urea cycle disorder.
    • Generic sodium phenylbutyrate was tried and failed, or is contraindicated; document the response or contraindication.
    • A documented dietary protein restriction plan is in place.
    Billing Rule

    Authorization Duration and FDA Labeling

    Initial authorization for all drugs listed in this policy, including a non-formulary exception review, may be approved for up to 12 months. The product must be prescribed and administered according to its FDA dosage and administration prescribing information.

    • Buphenyl, Carbaglu, generic carglumic acid, Olpruva, Pheburane, Ravicti, generic glycerol phenylbutyrate, and generic sodium phenylbutyrate may be approved for up to 3 years when drug-specific criteria are met and chart notes show continued positive clinical response.
    • Non-formulary exception authorizations may be approved for up to 12 months.
    • Prescribing must comply with the product's current FDA labeling.
    Step Therapy

    Preferred Generic Sodium Phenylbutyrate

    Trial generic sodium phenylbutyrate before requesting Buphenyl, Olpruva, or Pheburane, unless the request documents the required inadequate response or intolerance to generic therapy.

    • Document the generic sodium phenylbutyrate trial and inadequate response or intolerance.
    • Submit the applicable chronic urea cycle disorder diagnosis, genetic testing, and dietary protein restriction plan.
    Step Therapy

    Preferred Generic Carglumic Acid

    Trial generic carglumic acid before requesting Carbaglu when Carbaglu is requested for NAGS deficiency or for acute hyperammonemia due to PA or MMA, unless the request documents the required inadequate response or intolerance.

    • Document the generic carglumic acid trial and inadequate response or intolerance.
    • For NAGS deficiency, submit genetic confirmation of hepatic NAGS deficiency.
    • For PA or MMA, document acute hyperammonemia and adjunctive use with standard of care.
    Step Therapy

    Preferred Sodium Phenylbutyrate

    Trial generic sodium phenylbutyrate before requesting Ravicti or generic glycerol phenylbutyrate, unless generic therapy is contraindicated.

    • Document failed generic sodium phenylbutyrate therapy or the contraindication.
    • Submit the chronic urea cycle disorder diagnosis and dietary protein restriction plan.
    Documentation Required

    Clinical Records Required

    Submit medical records that establish medical necessity for the requested drug and indication.

    • Office visit notes containing the diagnosis, relevant history, physical evaluation, and medication history.
    • Include current treatment response and other records needed to support the applicable drug-specific criteria.
    Documentation Required

    Drug-Specific Supporting Documentation

    Drug-specific supporting documentation must accompany the request whenever required by the requested product and indication.

    • Genetic testing: CPS, OTC, or AS deficiency for sodium phenylbutyrate products; hepatic NAGS deficiency for NAGS-related carglumic acid requests.
    • Prior therapy: documented trial of generic sodium phenylbutyrate before Buphenyl, Olpruva, Pheburane, Ravicti, or generic glycerol phenylbutyrate; documented trial of generic carglumic acid before Carbaglu.
    • Document inadequate response, intolerance, or contraindication where applicable.
    • Provide a dietary protein restriction plan for sodium phenylbutyrate, Loargys, and glycerol phenylbutyrate requests.
    • Provide laboratory evidence supporting Loargys eligibility, including persistently elevated plasma arginine or other qualifying ARG1-D evidence.
    Documentation Required

    Loargys Functional Assessments

    For Loargys requests, submit baseline functional assessments when required by age and include them in the clinical records.

    • Submit the baseline Gross Motor Function Measure part E (GMFM-E) score for individuals at least 5 years of age.
    • Submit the baseline 2-minute walk test (2MWT) result for individuals at least 5 years of age.
    • GMFM-E evaluates walking, running, and jumping on a 0–72 scale; lower scores indicate greater impairment.
    • GMFM-E and 2MWT baseline values are not required for individuals younger than 5 years.
    Denial Risk

    Unlisted or Unsupported Use

    All other uses of the medications listed in this policy are considered investigational and are not covered under the stated medical-necessity criteria.

    • Do not submit unlisted or unsupported indications as covered treatment.
    • Coverage remains subject to the product's FDA dosage and administration prescribing information.
    Denial Risk

    Failure to Meet Drug-Specific Criteria

    Requests may be denied when drug-specific coverage requirements are not met or the supporting records are incomplete.

    • The required diagnosis or genetic confirmation is absent.
    • Required dietary protein restriction documentation is absent.
    • Required prior generic-drug trial, inadequate response, intolerance, or contraindication is not documented.
    • The submitted records do not support the requested indication or chronic/acute treatment requirement.
    Denial Risk

    Insufficient Response for Reauthorization

    Loargys reauthorization may be denied when the required biochemical or functional response is not documented.

    • Plasma arginine is not documented at less than 200 micromoles per liter.
    • For individuals at least 5 years of age, the GMFM-E score does not show improvement from baseline.
    • For individuals at least 5 years of age, the 2MWT does not show improvement from baseline.
    • Reauthorization reviews for Loargys may be approved for up to 12 months when these requirements are documented.
    NAGS deficiency
    AbbreviationNAGS
    Full termN-acetylglutamate synthase
    Deficiency contextNAGS deficiency is a urea cycle disorder associated with hyperammonemia
    PA
    AbbreviationPA
    Full termPropionic acidemia
    Policy contextA cause of acute hyperammonemia addressed in the Carbaglu evidence
    MMA
    AbbreviationMMA
    Full termMethylmalonic acidemia
    Policy contextA cause of acute hyperammonemia addressed in the Carbaglu evidence
    ARG1-D
    AbbreviationARG1-D
    Full termArginase 1 deficiency
    Treatment contextThe documented deficiency associated with hyperargininemia treated with Loargys
    OTC
    AbbreviationOTC
    Full termOrnithine transcarbamylase deficiency
    Disease contextA urea cycle disorder subtype addressed in glycerol phenylbutyrate evidence
    CPS
    AbbreviationCPS
    Full termCarbamoyl phosphate synthetase deficiency
    Disease contextA urea cycle disorder subtype addressed in glycerol phenylbutyrate evidence
    AS
    AbbreviationAS
    Full termArgininosuccinic acid synthetase deficiency
    Disease contextA urea cycle disorder subtype addressed in glycerol phenylbutyrate evidence
    ASL
    AbbreviationASL
    Full termArgininosuccinate lyase deficiency
    Disease contextA urea cycle disorder subtype addressed in glycerol phenylbutyrate evidence

    Loargys reviews may be approved for up to 12 months.